226 related articles for article (PubMed ID: 34801283)
1. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
Stein MD; VanNoppen D; Herman DS; Anderson BJ; Conti M; Bailey GL
J Subst Abuse Treat; 2022 May; 136():108661. PubMed ID: 34801283
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
[TBL] [Abstract][Full Text] [Related]
3. Use of long-acting injectable buprenorphine in the correctional setting.
Martin RA; Berk J; Rich JD; Kang A; Fritsche J; Clarke JG
J Subst Abuse Treat; 2022 Nov; 142():108851. PubMed ID: 35939914
[TBL] [Abstract][Full Text] [Related]
4. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series.
Peckham AM; Kehoe LG; Gray JR; Wakeman SE
J Subst Abuse Treat; 2021 Jul; 126():108316. PubMed ID: 34116808
[TBL] [Abstract][Full Text] [Related]
7. Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series.
Hansen ER; South AM; Lofwall MR; Fanucchi LC
J Addict Med; 2024 Jan-Feb 01; 18(1):65-67. PubMed ID: 37874645
[TBL] [Abstract][Full Text] [Related]
8. The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study.
Langlois J; Nolan S; Dickhout P; Cui Z; Paterson J; Fairbairn N; Socías ME
Subst Use Addctn J; 2024 Apr; 45(2):176-180. PubMed ID: 38254287
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
[TBL] [Abstract][Full Text] [Related]
11. Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine.
Rodriguez CP; Suzuki J
Am J Addict; 2023 May; 32(3):314-317. PubMed ID: 36941795
[TBL] [Abstract][Full Text] [Related]
12. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
Mariani JJ; Dobbins RL; Heath A; Gray F; Hassman H
Am J Addict; 2024 Jan; 33(1):8-14. PubMed ID: 37936553
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
[TBL] [Abstract][Full Text] [Related]
14. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2024 May; 127():104390. PubMed ID: 38522175
[TBL] [Abstract][Full Text] [Related]
15. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Kosten T; Aharonovich E; Nangia N; Zavod A; Akerman SC; Lopez-Bresnahan M; Sullivan MA
Addict Behav; 2020 Dec; 111():106538. PubMed ID: 32777606
[TBL] [Abstract][Full Text] [Related]
16. Extended-release buprenorphine outcomes among treatment resistant veterans.
Cotton AJ; Lo K; Kurtz FB; Waldbauer L
Am J Drug Alcohol Abuse; 2022 May; 48(3):334-337. PubMed ID: 34780319
[No Abstract] [Full Text] [Related]
17. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2022 Feb; 100():103492. PubMed ID: 34736130
[TBL] [Abstract][Full Text] [Related]
20. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
